Medicine and Dentistry
Diabetic Nephropathy
100%
Cost-Effectiveness Analysis
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Health Care Cost
57%
Quality Adjusted Life Year
42%
Diabetes
28%
Cardiovascular Disease
14%
Nephropathy
14%
Clinical Trial
14%
Apoplexy
14%
Myocardial Infarction
14%
Drug Therapy
14%
Congestive Heart Failure
14%
Monte Carlo Method
14%
Canagliflozin
14%
Evaluation Study
14%
Nursing and Health Professions
Diabetic Nephropathy
100%
Cost Effectiveness Analysis
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Quality Adjusted Life Year
42%
Kidney Disease
14%
Clinical Evaluation
14%
Drug Therapy
14%
Clinical Practice
14%
Independent Practice Association
14%
Cardiovascular Disease
14%
Heart Infarction
14%
Cerebrovascular Accident
14%
Health Care Cost
14%
Incremental Cost-Effectiveness Ratio
14%
Congestive Heart Failure
14%
Canagliflozin
14%
Evaluation Study
14%
Monte Carlo Method
14%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetic Nephropathy
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Pharmacotherapy
14%
Clinical Trial
14%
Heart Infarction
14%
Congestive Heart Failure
14%
Cerebrovascular Accident
14%
Kidney Disease
14%
Canagliflozin
14%
Cardiovascular Disease
14%
Keyphrases
Clinical Evaluation Study
14%